The unique characteristics of Nanobodies and continuous innovation have allowed Ablynx, and its partners, to develop differentiated drug products such as both antagonistic and agonistic Nanobodies, bispecific Nanobodies, Nanobodies against challenging targets such as ion channels and GPCRs, Nanobodies that are administered through alternative routes of administration and Nanobodies half-lives which can be modulated from hours to days to weeks.

To date, Ablynx has generated Nanobodies against more than 235 different disease targets and has characterized potent antagonists in vitro against 38 different targets. The Company and its collaborators have obtained positive in vivo efficacy data from animal studies in eight major therapeutic programs in five disease areas.

Ablynx’s in-house lead programs in the clinic, ozoralizumab, caplacizumab, and ALX-0061 are in Phase II clinical development. Ablynx’s clinical development program ALX-0141 has recently completed Phase I trials. ALX-0141 has been developed to inhibit bone loss associated with post-menopausal osteoporosis, rheumatoid arthritis, cancer and certain drugs. Another Nanobody in clinical development is ATN-192 (formerly known as PF-05230905), and Phase I results are expected during the first half of 2012. Finally, in December 2011, a Phase I study with the first inhaled Nanobody, ALX-0171, was initiated. ALX-0171 has the potential to be a first-in-class therapeutic to treat s (RSV).

In parallel with its internally developed products, Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies, including Boehringer Ingelheim, Merck Serono, and Novartis. Ablynx is building a diverse and broad portfolio of therapeutic Nanobodies through these collaborations.